Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARINA: Ranibizumab in Minimally Classic or Occult AMD
NCT00056836Phase 3Completed
- Sponsor
- Genentech
- Start
- Mar 2003
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Genentech. Primary endpoint: Proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. Started Mar 2003; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00056836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056836.